Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on oncology therapeutics, announced that its annual meeting of shareholders will be held virtually at 9 a.m. PDT on June 29, 2026. Meeting materials will be mailed following their finalization and filing with the Securities and Exchange Commission (SEC). In a separate disclosure, the company revealed that its 2025 annual report included an audit report containing a going concern explanatory paragraph from its independent registered public accounting firm, as required under Section 610(b) of the NYSE American Company Guide. The company emphasized that this disclosure does not reflect any change or amendment to previously filed financial statements.
The going concern notice signals that there is substantial doubt about Kairos Pharma's ability to continue as a going concern, a common issue for clinical-stage biotech firms that have yet to generate revenue from product sales. For investors and industry observers, this highlights the financial risks inherent in drug development, particularly for companies like Kairos Pharma that are advancing candidates through early-stage trials. The disclosure may affect the company's stock price and its ability to raise capital, which is critical for funding ongoing research and development activities.
Kairos Pharma is based in Los Angeles, California, and leverages structural biology to address drug resistance and immune suppression in cancer. Its lead candidate, ENV-105, is an antibody targeting CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy. The company aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. ENV-105 is currently in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer, addressing significant unmet medical needs. However, as of the date of the press release, ENV-105 has not been approved as safe or effective by the U.S. Food and Drug Administration (FDA) or any other comparable foreign regulator.
The announcement comes amid a challenging environment for small-cap biotech firms, which often face high cash burn rates and reliance on external financing. For the industry, Kairos Pharma's situation underscores the precarious nature of early-stage drug development, where regulatory milestones and clinical data releases are pivotal for survival. Investors will likely monitor the company's progress in its clinical trials and any financing activities that could alleviate the going concern risk.
For more details, the full press release is available at https://ibn.fm/sQ0pm. Additional updates on Kairos Pharma can be found in the company’s newsroom at https://ibn.fm/KAPA.
